Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. 1991. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: Implications for prevention of HIV. The International Journal of Addictions. 26(12):1313– 1320.
Washton AM, Pottash AC, Gold MS. 1984. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry. 45(9 pt 2):39–41.
WHO (World Health Organization). 2004a. Evidence for Action: Effectiveness of Community-Based Outreach in Preventing HIV/AIDS Among Injecting Drug Users. Geneva, Switzerland: WHO.
WHO. 2004b. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Guidelines on Care, Treatment and Support for Women Living with Hiv/Aids and Their Children in Resource-Constrained Settings. Geneva, Switzerland: WHO.
WHO. 2005a. Evidence for Action: Effectiveness of Drug Dependence Treatment in Preventing HIV Among Injecting Drug Users. Geneva, Switzerland: WHO.
WHO. 2005b. Policy and Programming Guide for HIV/AIDS Prevention and Care Among Injecting Drug Users. Geneva, Switzerland: WHO.
WHO. 2005c. WHO Model List of Essential Medicine. 14th edition. [Online]. Available: http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf [accessed August 11, 2006].
WHO, UNODC, UNAIDS. 2004. Substitution Maintenance Therapy in the Management of Opioid Dependence and HIV/AIDS Prevention: Position Paper. Geneva, Switzerland: WHO.
Wiebel WW, Jimenez A, Johnson W, Ouellet L, Jovanovic B, Lampinen T, Murray J, O’Brien MU. 1996. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 12(3):282–289.
Williams AB, McNelly EA, Williams AE, D’Aquila RT. 1992. Methadone maintenance treatment and HIV type 1 seroconversion among injecting drug users. AIDS Care. 4(1): 35–41.